LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Biogen Inc

Biogen Inc

Closed

Sector Healthcare

211.03 -7.3

Buy Sell

Overview

Share price change

24h

Current

Min

210.54

Max

227.06

Key metrics
By Trading Economics
Income	144M 393M
Sales	-96M 2.3B
P/E Sector Avg	27.06 79.786
EPS	3.67
Profit margin	17.179
Employees	7,570
EBITDA	29M 682M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+24.02 upside

Dividends
By Dow Jones
Next Earnings	1 Aug 2024

Market Stats
By TradingEconomics
Market Cap	-916M 32B
Previous open	218.33
Previous close	211.03

News Sentiment

By Acuity

51%

49%

296 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

223.3 / 228.57 Support & Resistance

Biogen Inc Chart

Related News

7 Aug 2023, 12:03 UTC

Major Market Movers

Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback

29 May 2024, 15:56 UTC

Earnings

Acquisitions, Mergers, Takeovers

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4 Oct 2023, 17:55 UTC

Acquisitions, Mergers, Takeovers

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

1 Sept 2023, 15:23 UTC

Acquisitions, Mergers, Takeovers

Why Amgen's $28 Billion Merger News Also Bodes Well For Pfizer, Biogen -- IBD

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

24.02% upside

12 Months Forecast

Average 282.06 USD 24.02%

High 342 USD

Low 200 USD

Based on 19 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Biogen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

223.3 / 228.57Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

296 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.